Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 273

1.

Corrigendum to Preclinical models for precision oncology. BBACAN 1870/2 (2018) 239-246.

Ibarrola-Villava M, Cervantes A, Bardelli A.

Biochim Biophys Acta Rev Cancer. 2019 May 25. pii: S0304-419X(19)30082-4. doi: 10.1016/j.bbcan.2019.05.002. [Epub ahead of print] No abstract available.

PMID:
31138435
2.

TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma.

Goyal L, Shi L, Liu LY, Fece de la Cruz F, Lennerz JK, Raghavan S, Leshchiner I, Elagina L, Siravegna G, Ng RWS, Vu P, Patra KC, Saha SK, Uppot RN, Arellano R, Reyes S, Sagara T, Otsuki S, Nadres B, Shahzade HA, Dey-Guha I, Fetter IJ, Baiev I, Van Seventer EE, Murphy JE, Ferrone CR, Tanabe KK, Deshpande V, Harding JJ, Yaeger R, Kelley RK, Bardelli A, Iafrate AJ, Hahn WC, Benes CH, Ting DT, Hirai H, Getz G, Juric D, Zhu AX, Corcoran RB, Bardeesy N.

Cancer Discov. 2019 May 20. pii: CD-19-0182. doi: 10.1158/2159-8290.CD-19-0182. [Epub ahead of print]

PMID:
31109923
3.

A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology.

Corti G, Bartolini A, Crisafulli G, Novara L, Rospo G, Montone M, Negrino C, Mussolin B, Buscarino M, Isella C, Barault L, Siravegna G, Siena S, Marsoni S, Di Nicolantonio F, Medico E, Bardelli A.

Clin Colorectal Cancer. 2019 Jun;18(2):91-101.e3. doi: 10.1016/j.clcc.2019.02.008. Epub 2019 Mar 7.

PMID:
30981604
4.

Review: Peering through a keyhole: liquid biopsy in primary and metastatic central nervous system tumours.

Bertero L, Siravegna G, Rudà R, Soffietti R, Bardelli A, Cassoni P.

Neuropathol Appl Neurobiol. 2019 Apr 12. doi: 10.1111/nan.12553. [Epub ahead of print] Review.

PMID:
30977933
5.

HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer.

Sartore-Bianchi A, Amatu A, Porcu L, Ghezzi S, Lonardi S, Leone F, Bergamo F, Fenocchio E, Martinelli E, Borelli B, Tosi F, Racca P, Valtorta E, Bonoldi E, Martino C, Vaghi C, Marrapese G, Ciardiello F, Zagonel V, Bardelli A, Trusolino L, Torri V, Marsoni S, Siena S.

Oncologist. 2019 Apr 5. pii: theoncologist.2018-0785. doi: 10.1634/theoncologist.2018-0785. [Epub ahead of print]

PMID:
30952821
6.

Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer.

Siravegna G, Sartore-Bianchi A, Nagy RJ, Raghav K, Odegaard JI, Lanman RB, Trusolino L, Marsoni S, Siena S, Bardelli A.

Clin Cancer Res. 2019 May 15;25(10):3046-3053. doi: 10.1158/1078-0432.CCR-18-3389. Epub 2019 Feb 26.

PMID:
30808777
7.

Exploiting DNA repair defects in colorectal cancer.

Reilly NM, Novara L, Di Nicolantonio F, Bardelli A.

Mol Oncol. 2019 Apr;13(4):681-700. doi: 10.1002/1878-0261.12467. Epub 2019 Mar 2. Review.

8.

Use of a Dual mobility cup to prevent hip early arthroplasty dislocation in patients at high falls risk.

Nonne D, Sanna F, Bardelli A, Milano P, Rivera F.

Injury. 2019 Jan 18. pii: S0020-1383(19)30011-7. doi: 10.1016/j.injury.2019.01.022. [Epub ahead of print]

PMID:
30691923
9.

Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies.

Mauri G, Pizzutilo EG, Amatu A, Bencardino K, Palmeri L, Bonazzina EF, Tosi F, Carlo Stella G, Burrafato G, Scaglione F, Marsoni S, Siravegna G, Bardelli A, Siena S, Sartore-Bianchi A.

Cancer Treat Rev. 2019 Feb;73:41-53. doi: 10.1016/j.ctrv.2018.12.006. Epub 2018 Dec 27.

PMID:
30616224
10.

Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases.

Seoane J, De Mattos-Arruda L, Le Rhun E, Bardelli A, Weller M.

Ann Oncol. 2019 Feb 1;30(2):211-218. doi: 10.1093/annonc/mdy544.

PMID:
30576421
11.

Early-onset colorectal cancer in young individuals.

Mauri G, Sartore-Bianchi A, Russo AG, Marsoni S, Bardelli A, Siena S.

Mol Oncol. 2019 Feb;13(2):109-131. doi: 10.1002/1878-0261.12417. Epub 2018 Dec 22. Review.

12.

Inactivation of DNA repair-prospects for boosting cancer immune surveillance.

Truini A, Germano G, Bardelli A.

Genome Med. 2018 Nov 28;10(1):91. doi: 10.1186/s13073-018-0603-9.

13.

Failure is not final: ctDNA-guided rechallenge therapy in colorectal cancer.

Siravegna G, Bardelli A.

Ann Oncol. 2019 Feb 1;30(2):157-159. doi: 10.1093/annonc/mdy525. No abstract available.

PMID:
30475974
14.

The Clinical Impact of the Genomic Landscape of Mismatch Repair-Deficient Cancers.

Germano G, Amirouchene-Angelozzi N, Rospo G, Bardelli A.

Cancer Discov. 2018 Dec;8(12):1518-1528. doi: 10.1158/2159-8290.CD-18-0150. Epub 2018 Nov 15. Review.

PMID:
30442708
15.

Correction: Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.

Costa-Cabral S, Brough R, Konde A, Aarts M, Campbell J, Marinari E, Riffell J, Bardelli A, Torrance C, Lord CJ, Ashworth A.

PLoS One. 2018 Oct 26;13(10):e0206729. doi: 10.1371/journal.pone.0206729. eCollection 2018.

16.

Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group.

Grignani G, D'Ambrosio L, Pignochino Y, Palmerini E, Zucchetti M, Boccone P, Aliberti S, Stacchiotti S, Bertulli R, Piana R, Miano S, Tolomeo F, Chiabotto G, Sangiolo D, Pisacane A, Dei Tos AP, Novara L, Bartolini A, Marchesi E, D'Incalci M, Bardelli A, Picci P, Ferrari S, Aglietta M.

Lancet Oncol. 2018 Oct;19(10):1360-1371. doi: 10.1016/S1470-2045(18)30438-8. Epub 2018 Sep 11.

PMID:
30217671
17.

Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade.

Lo Russo G, Moro M, Sommariva M, Cancila V, Boeri M, Centonze G, Ferro S, Ganzinelli M, Gasparini P, Huber V, Milione M, Porcu L, Proto C, Pruneri G, Signorelli D, Sangaletti S, Sfondrini L, Storti C, Tassi E, Bardelli A, Marsoni S, Torri V, Tripodo C, Colombo MP, Anichini A, Rivoltini L, Balsari A, Sozzi G, Garassino MC.

Clin Cancer Res. 2019 Feb 1;25(3):989-999. doi: 10.1158/1078-0432.CCR-18-1390. Epub 2018 Sep 11.

PMID:
30206165
18.

Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer.

Siravegna G, Lazzari L, Crisafulli G, Sartore-Bianchi A, Mussolin B, Cassingena A, Martino C, Lanman RB, Nagy RJ, Fairclough S, Rospo G, Corti G, Bartolini A, Arcella P, Montone M, Lodi F, Lorenzato A, Vanzati A, Valtorta E, Cappello G, Bertotti A, Lonardi S, Zagonel V, Leone F, Russo M, Balsamo A, Truini M, Di Nicolantonio F, Amatu A, Bonazzina E, Ghezzi S, Regge D, Vanzulli A, Trusolino L, Siena S, Marsoni S, Bardelli A.

Cancer Cell. 2018 Jul 9;34(1):148-162.e7. doi: 10.1016/j.ccell.2018.06.004.

PMID:
29990497
19.

Preclinical models for precision oncology.

Ibarrola-Villava M, Cervantes A, Bardelli A.

Biochim Biophys Acta Rev Cancer. 2018 Dec;1870(2):239-246. doi: 10.1016/j.bbcan.2018.06.004. Epub 2018 Jun 28. Review. Erratum in: Biochim Biophys Acta Rev Cancer. 2019 May 25;:.

PMID:
29959990
20.

Exploring the links between cancer and placenta development.

Costanzo V, Bardelli A, Siena S, Abrignani S.

Open Biol. 2018 Jun;8(6). pii: 180081. doi: 10.1098/rsob.180081. Review.

21.

Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies.

Russo M, Lamba S, Lorenzato A, Sogari A, Corti G, Rospo G, Mussolin B, Montone M, Lazzari L, Arena S, Oddo D, Linnebacher M, Sartore-Bianchi A, Pietrantonio F, Siena S, Di Nicolantonio F, Bardelli A.

Nat Commun. 2018 Jun 12;9(1):2287. doi: 10.1038/s41467-018-04506-z.

22.

SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.

Mainardi S, Mulero-Sánchez A, Prahallad A, Germano G, Bosma A, Krimpenfort P, Lieftink C, Steinberg JD, de Wit N, Gonçalves-Ribeiro S, Nadal E, Bardelli A, Villanueva A, Bernards R.

Nat Med. 2018 Jul;24(7):961-967. doi: 10.1038/s41591-018-0023-9. Epub 2018 May 28.

PMID:
29808006
23.

Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer.

Knickelbein K, Tong J, Chen D, Wang YJ, Misale S, Bardelli A, Yu J, Zhang L.

Oncogene. 2018 Aug;37(33):4599-4610. doi: 10.1038/s41388-018-0289-x. Epub 2018 May 14.

24.

Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer.

Siena S, Sartore-Bianchi A, Marsoni S, Hurwitz HI, McCall SJ, Penault-Llorca F, Srock S, Bardelli A, Trusolino L.

Ann Oncol. 2018 May 1;29(5):1108-1119. doi: 10.1093/annonc/mdy100.

25.

RET fusions in a small subset of advanced colorectal cancers at risk of being neglected.

Pietrantonio F, Di Nicolantonio F, Schrock AB, Lee J, Morano F, Fuca G, Nikolinakos P, Drilon A, Hechtman JF, Christiansen J, Gowen K, Frampton GM, Gasparini P, Rossini D, Gigliotti C, Kim ST, Prisciandaro M, Hodgson J, Zaniboni A, Chiu VK, Milione M, Patel R, Miller V, Bardelli A, Novara L, Wang L, Pupa SM, Sozzi G, Ross J, Di Bartolomeo M, Bertotti A, Ali S, Trusolino L, Falcone A, de Braud F, Cremolini C.

Ann Oncol. 2018 Jun 1;29(6):1394-1401. doi: 10.1093/annonc/mdy090.

26.

Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial.

Montagut C, Argilés G, Ciardiello F, Poulsen TT, Dienstmann R, Kragh M, Kopetz S, Lindsted T, Ding C, Vidal J, Clausell-Tormos J, Siravegna G, Sánchez-Martín FJ, Koefoed K, Pedersen MW, Grandal MM, Dvorkin M, Wyrwicz L, Rovira A, Cubillo A, Salazar R, Desseigne F, Nadal C, Albanell J, Zagonel V, Siena S, Fumi G, Rospo G, Nadler P, Horak ID, Bardelli A, Tabernero J.

JAMA Oncol. 2018 Apr 12;4(4):e175245. doi: 10.1001/jamaoncol.2017.5245. Epub 2018 Apr 12. Erratum in: JAMA Oncol. 2019 May 1;5(5):745.

27.

Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case.

Martinelli E, Troiani T, Sforza V, Martini G, Cardone C, Vitiello PP, Ciardiello D, Rachiglio AM, Normanno N, Sartore-Bianchi A, Marsoni S, Bardelli A, Siena S, Ciardiello F.

ESMO Open. 2018 Jan 10;3(1):e000299. doi: 10.1136/esmoopen-2017-000299. eCollection 2018. Erratum in: ESMO Open. 2019 Apr 12;4(2):e000299corr1.

28.

ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.

Pietrantonio F, Di Nicolantonio F, Schrock AB, Lee J, Tejpar S, Sartore-Bianchi A, Hechtman JF, Christiansen J, Novara L, Tebbutt N, Fucà G, Antoniotti C, Kim ST, Murphy D, Berenato R, Morano F, Sun J, Min B, Stephens PJ, Chen M, Lazzari L, Miller VA, Shoemaker R, Amatu A, Milione M, Ross JS, Siena S, Bardelli A, Ali SM, Falcone A, de Braud F, Cremolini C.

J Natl Cancer Inst. 2017 Dec 1;109(12). doi: 10.1093/jnci/djx089.

PMID:
29370427
29.

Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges.

Bradley CA, Salto-Tellez M, Laurent-Puig P, Bardelli A, Rolfo C, Tabernero J, Khawaja HA, Lawler M, Johnston PG, Van Schaeybroeck S; MErCuRIC consortium.

Nat Rev Clin Oncol. 2018 Jan 23;15(3):150. doi: 10.1038/nrclinonc.2018.13. [Epub ahead of print]

PMID:
29358775
30.

Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer.

Germano G, Mauri G, Siravegna G, Dive C, Pierce J, Di Nicolantonio F, D'Incalci M, Bardelli A, Siena S, Sartore-Bianchi A.

Clin Colorectal Cancer. 2018 Mar;17(1):80-83. doi: 10.1016/j.clcc.2017.10.017. Epub 2017 Nov 1.

PMID:
29195807
31.

Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth.

Germano G, Lamba S, Rospo G, Barault L, Magrì A, Maione F, Russo M, Crisafulli G, Bartolini A, Lerda G, Siravegna G, Mussolin B, Frapolli R, Montone M, Morano F, de Braud F, Amirouchene-Angelozzi N, Marsoni S, D'Incalci M, Orlandi A, Giraudo E, Sartore-Bianchi A, Siena S, Pietrantonio F, Di Nicolantonio F, Bardelli A.

Nature. 2017 Dec 7;552(7683):116-120. doi: 10.1038/nature24673. Epub 2017 Nov 29.

PMID:
29186113
32.

Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases.

Siravegna G, Geuna E, Mussolin B, Crisafulli G, Bartolini A, Galizia D, Casorzo L, Sarotto I, Scaltriti M, Sapino A, Bardelli A, Montemurro F.

ESMO Open. 2017 Oct 9;2(4):e000253. doi: 10.1136/esmoopen-2017-000253. eCollection 2017.

33.

Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer.

Barault L, Amatu A, Siravegna G, Ponzetti A, Moran S, Cassingena A, Mussolin B, Falcomatà C, Binder AM, Cristiano C, Oddo D, Guarrera S, Cancelliere C, Bustreo S, Bencardino K, Maden S, Vanzati A, Zavattari P, Matullo G, Truini M, Grady WM, Racca P, Michels KB, Siena S, Esteller M, Bardelli A, Sartore-Bianchi A, Di Nicolantonio F.

Gut. 2018 Nov;67(11):1995-2005. doi: 10.1136/gutjnl-2016-313372. Epub 2017 Oct 5.

34.

Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer.

Siena S, Sartore-Bianchi A, Garcia-Carbonero R, Karthaus M, Smith D, Tabernero J, Van Cutsem E, Guan X, Boedigheimer M, Ang A, Twomey B, Bach BA, Jung AS, Bardelli A.

Ann Oncol. 2018 Jan 1;29(1):119-126. doi: 10.1093/annonc/mdx504.

35.

Tumor Evolution as a Therapeutic Target.

Amirouchene-Angelozzi N, Swanton C, Bardelli A.

Cancer Discov. 2017 Jul 20. doi: 10.1158/2159-8290.CD-17-0343. [Epub ahead of print] Review.

36.

Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer.

Oddo D, Siravegna G, Gloghini A, Vernieri C, Mussolin B, Morano F, Crisafulli G, Berenato R, Corti G, Volpi CC, Buscarino M, Niger M, Dunne PD, Rospo G, Valtorta E, Bartolini A, Fucà G, Lamba S, Martinetti A, Di Bartolomeo M, de Braud F, Bardelli A, Pietrantonio F, Di Nicolantonio F.

Br J Cancer. 2017 Jul 25;117(3):347-352. doi: 10.1038/bjc.2017.196. Epub 2017 Jun 27.

37.

Liquid Biopsies for Monitoring Temporal Genomic Heterogeneity in Breast and Colon Cancers.

Venesio T, Siravegna G, Bardelli A, Sapino A.

Pathobiology. 2018;85(1-2):146-154. doi: 10.1159/000473882. Epub 2017 Jun 15. Review.

38.

Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance.

Ali M, Kaltenbrun E, Anderson GR, Stephens SJ, Arena S, Bardelli A, Counter CM, Wood KC.

Nat Commun. 2017 Jun 8;8:15617. doi: 10.1038/ncomms15617.

39.

Medical research: Personalized test tracks cancer relapse.

Bardelli A.

Nature. 2017 May 24;545(7655):417-418. doi: 10.1038/545417a. No abstract available. Erratum in: Nature. 2017 Jul 26;547(7664):412.

PMID:
28541318
40.

Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.

Costa-Cabral S, Brough R, Konde A, Aarts M, Campbell J, Marinari E, Riffell J, Bardelli A, Torrance C, Lord CJ, Ashworth A.

PLoS One. 2017 Apr 20;12(4):e0176578. doi: 10.1371/journal.pone.0176578. eCollection 2017. Erratum in: PLoS One. 2018 Oct 26;13(10):e0206729.

41.

Tracking colorectal cancer evolution in time and space.

Rospo G, Corti G, Crisafulli G, Novara L, Bardelli A.

Ann Oncol. 2017 Jun 1;28(6):1163-1165. doi: 10.1093/annonc/mdx127. No abstract available.

PMID:
28383707
42.

Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges.

Bradley CA, Salto-Tellez M, Laurent-Puig P, Bardelli A, Rolfo C, Tabernero J, Khawaja HA, Lawler M, Johnston PG, Van Schaeybroeck S; MErCuRIC consortium.

Nat Rev Clin Oncol. 2017 Sep;14(9):562-576. doi: 10.1038/nrclinonc.2017.40. Epub 2017 Apr 4. Review. Erratum in: Nat Rev Clin Oncol. 2018 Jan 23;:.

PMID:
28374784
43.

Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor.

Siravegna G, Sartore-Bianchi A, Mussolin B, Cassingena A, Amatu A, Novara L, Buscarino M, Corti G, Crisafulli G, Bartolini A, Tosi F, Erlander M, Di Nicolantonio F, Siena S, Bardelli A.

Ann Oncol. 2017 Jun 1;28(6):1302-1308. doi: 10.1093/annonc/mdx095.

44.

Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients.

Carbone C, Piro G, Simionato F, Ligorio F, Cremolini C, Loupakis F, Alì G, Rossini D, Merz V, Santoro R, Zecchetto C, Zanotto M, Di Nicolantonio F, Bardelli A, Fontanini G, Tortora G, Melisi D.

Clin Cancer Res. 2017 Aug 1;23(15):4312-4322. doi: 10.1158/1078-0432.CCR-16-3153. Epub 2017 Mar 15.

45.

Integrating liquid biopsies into the management of cancer.

Siravegna G, Marsoni S, Siena S, Bardelli A.

Nat Rev Clin Oncol. 2017 Sep;14(9):531-548. doi: 10.1038/nrclinonc.2017.14. Epub 2017 Mar 2. Review.

PMID:
28252003
46.

Liquid Biopsies, What We Do Not Know (Yet).

Bardelli A, Pantel K.

Cancer Cell. 2017 Feb 13;31(2):172-179. doi: 10.1016/j.ccell.2017.01.002. Review.

47.

Loss of AXIN1 drives acquired resistance to WNT pathway blockade in colorectal cancer cells carrying RSPO3 fusions.

Picco G, Petti C, Centonze A, Torchiaro E, Crisafulli G, Novara L, Acquaviva A, Bardelli A, Medico E.

EMBO Mol Med. 2017 Mar;9(3):293-303. doi: 10.15252/emmm.201606773.

48.

Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers.

Fujii T, Barzi A, Sartore-Bianchi A, Cassingena A, Siravegna G, Karp DD, Piha-Paul SA, Subbiah V, Tsimberidou AM, Huang HJ, Veronese S, Di Nicolantonio F, Pingle S, Vibat CRT, Hancock S, Berz D, Melnikova VO, Erlander MG, Luthra R, Kopetz ES, Meric-Bernstam F, Siena S, Lenz HJ, Bardelli A, Janku F.

Clin Cancer Res. 2017 Jul 15;23(14):3657-3666. doi: 10.1158/1078-0432.CCR-16-2592. Epub 2017 Jan 17.

49.

Lemur tyrosine kinase 2 (LMTK2) is a determinant of cell sensitivity to apoptosis by regulating the levels of the BCL2 family members.

Conti A, Majorini MT, Fontanella E, Bardelli A, Giacca M, Delia D, Mano M, Lecis D.

Cancer Lett. 2017 Mar 28;389:59-69. doi: 10.1016/j.canlet.2016.12.025. Epub 2016 Dec 29.

PMID:
28040547
50.

Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.

Goyal L, Saha SK, Liu LY, Siravegna G, Leshchiner I, Ahronian LG, Lennerz JK, Vu P, Deshpande V, Kambadakone A, Mussolin B, Reyes S, Henderson L, Sun JE, Van Seventer EE, Gurski JM Jr, Baltschukat S, Schacher-Engstler B, Barys L, Stamm C, Furet P, Ryan DP, Stone JR, Iafrate AJ, Getz G, Porta DG, Tiedt R, Bardelli A, Juric D, Corcoran RB, Bardeesy N, Zhu AX.

Cancer Discov. 2017 Mar;7(3):252-263. doi: 10.1158/2159-8290.CD-16-1000. Epub 2016 Dec 29.

Supplemental Content

Loading ...
Support Center